Valery Attignon
Overview
Explore the profile of Valery Attignon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
699
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Morin C, Paraqindes H, Nguyen Van Long F, Isaac C, Thomas E, Pedri D, et al.
NAR Cancer
. 2025 Jan;
7(1):zcaf001.
PMID: 39877292
The epithelial-mesenchymal transition (EMT) is a dynamic transdifferentiation of epithelial cells into mesenchymal cells. EMT programs exhibit great diversity, based primarily on the distinct impact of molecular activities of the...
2.
Peter E, Treilleux I, Wucher V, Villagran-Garcia M, Dumez P, Pissaloux D, et al.
Neurol Neuroimmunol Neuroinflamm
. 2025 Jan;
12(2):e200367.
PMID: 39823556
Background And Objectives: Breast cancers (BCs) of patients with paraneoplastic neurologic syndromes and anti-Yo antibodies (Yo-PNS) overexpress human epidermal growth factor receptor 2 (HER2) and display genetic alterations and overexpression...
3.
Deligne C, Tourbez A, Benard F, Meyer S, Curt A, Gianesello M, et al.
Neuro Oncol
. 2025 Jan;
PMID: 39792378
Background: Brain tumors are the deadliest solid tumors in children and adolescents. Most of these tumors are glial in origin and exhibit strong heterogeneity, hampering the development of effective therapeutic...
4.
Huchede P, Meyer S, Berthelot C, Hamadou M, Bertrand-Chapel A, Rakotomalala A, et al.
Elife
. 2024 Oct;
12.
PMID: 39373720
Pediatric diffuse midline gliomas (pDMG) are an aggressive type of childhood cancer with a fatal outcome. Their major epigenetic determinism has become clear, notably with the identification of K27M mutations...
5.
Vanacker H, Connacher R, Meurgey A, Bollard J, Attignon V, Tirode F, et al.
J Immunother
. 2024 Sep;
48(1):27-31.
PMID: 39224047
Therapeutic options for synovial sarcoma (SyS) have not evolved for several decades and the efficacy of second-line treatments is very limited. The expression of a large family of proteins known...
6.
Sablin M, Gestraud P, Jonas S, Lamy C, Lacroix-Triki M, Bachelot T, et al.
Br J Cancer
. 2024 Aug;
131(6):1060-1067.
PMID: 39090361
Background: Copy number alterations (CNA) are acquired during the evolution of cancers from their early stage to metastatic stage. This study aims at analysing the clinical value of the identified...
7.
Bobin C, Iddir Y, Butterworth C, Masliah-Planchon J, Saint-Charles A, Bellini A, et al.
Clin Cancer Res
. 2024 May;
30(15):3316-3328.
PMID: 38787533
Purpose: The study of cell-free DNA (cfDNA) enables sequential analysis of tumor cell-specific genetic alterations in patients with neuroblastoma. Experimental Design: Eighteen patients with relapsing neuroblastoma having received lorlatinib, a...
8.
Dufresne A, Attignon V, Ferrari A, Tonon L, Boyault S, Tabone-Eglinger S, et al.
Cancer Med
. 2024 Mar;
13(7):e7115.
PMID: 38553950
Introduction: The objective was to determine the added value of comprehensive molecular profile by whole-exome and RNA sequencing (WES/RNA-Seq) in advanced and refractory cancer patients who had no molecular-based treatment...
9.
Vanacker H, Treilleux I, Schiffler C, Bieche I, Campone M, Patsouris A, et al.
Br J Cancer
. 2024 Jan;
130(4):613-619.
PMID: 38182687
Background: To identify patients most likely to respond to everolimus, a mammalian target of rapamycin (mTOR) inhibitor, a prospective biomarker study was conducted in hormone receptor-positive endocrine-resistant metastatic breast cancer...
10.
Savary C, Luciana L, Huchede P, Tourbez A, Coquet C, Broustal M, et al.
Cell Rep Med
. 2023 Dec;
4(12):101339.
PMID: 38118405
Rhabdomyosarcoma (RMS) is the main form of pediatric soft-tissue sarcoma. Its cure rate has not notably improved in the last 20 years following relapse, and the lack of reliable preclinical...